Age, Immunity, and Viral Markers: Defining Predictors of Functional Cure in HIV/HBV Coinfection

The Clinical Landscape of HIV/HBV Coinfection

The intersection of HIV and HBV infections represents one of the most complex challenges in clinical virology and hepatology. When both pathogens coexist, the natural progression of chronic hepatitis B is accelerated, leading to higher risks of cirrhosis, hepatocellular carcinoma, and terminal liver failure. Unlike HBV monoinfection, where nucleos(t)ide analogues often achieve long-term viral suppression and partial remission, the immune dysregulation inherent in HIV alters the dynamics of viral clearance. Functional cure, defined as the sustained loss of hepatitis B surface antigen (HBsAg) with or without anti-HBs seroconversion, has emerged as the ultimate endpoint. This goal reflects not merely suppression of viral DNA but reconstitution of host immune surveillance capable of controlling latent and integrated viral reservoirs.

Antiretroviral therapy (ART) containing tenofovir disoproxil fumarate (TDF) in combination with lamivudine (3TC) or emtricitabine (FTC) remains the global standard of care for coinfected individuals. Despite consistent suppression of HBV DNA in more than ninety percent of patients, only a small fraction attain HBsAg clearance. This disparity highlights the inadequacy of virological suppression as a therapeutic surrogate in coinfection, reinforcing the need to focus on immunological and host-specific determinants. Emerging evidence suggests that predictors of functional cure are multifactorial, involving virological, immunological, and demographic variables. Yet, consistency across ethnicities and geographies has been elusive.

The retrospective cohort conducted in mainland China represents the largest population of coinfected individuals systematically evaluated for predictors of HBsAg clearance. By anchoring their methodology in multivariate regression modeling and survival analyses, the investigators identified advanced age, elevated CD4 counts, and HBeAg positivity at baseline as significant determinants of functional cure. These findings suggest that immune reconstitution under ART, combined with distinct viral antigenic states, drives differential trajectories of clearance. Importantly, these predictors provide clinicians with potential biomarkers for stratifying patient prognosis and optimizing treatment expectations.

This landscape positions functional cure not only as a virological event but also as an immune-restorative phenomenon. The study reframes the discussion of HIV/HBV management away from numerical viral suppression toward the biological interplay of age-dependent immune remodeling, CD4-driven host defense, and viral antigenic phase. The findings extend beyond cohort boundaries, setting a precedent for applying integrated predictors in global management strategies.

Methodological Framework and Patient Cohort Design

The study spanned nearly two decades and enrolled 431 patients from Beijing Youan Hospital, representing a rigorously defined population of HIV/HBV coinfected individuals. Inclusion criteria mandated persistent HBsAg positivity and receipt of TDF-based ART regimens, ensuring uniformity of therapeutic exposure. The majority of participants were male and acquired HIV via MSM transmission, reflecting the epidemiological profile of urban Chinese cohorts. Follow-up extended beyond six years, providing a long temporal window for observing HBsAg dynamics under sustained antiviral pressure. The investigators adhered to strict exclusion criteria to minimize confounding, including removal of acute HBV cases and non-standard therapy exposures.

HBV infection was monitored using sensitive immunoassays for HBsAg and polymerase chain reaction techniques for viral DNA quantification. Parallel measurement of liver enzymes and fibrosis indices contextualized hepatic injury, while HIV progression markers such as CD4 counts and viral load provided insights into host immune competence. This dual-axis evaluation underscored the study’s rigor, balancing viral kinetics with immunological correlates. Notably, the endpoint definition of HBsAg loss ensured alignment with the concept of functional cure rather than surrogate endpoints of DNA suppression.

Statistical modeling was central to interpreting the dataset. Logistic regression quantified associations between baseline clinical factors and HBsAg clearance, while Cox regression extended analysis to temporal kinetics. Subgroup analyses dissected interactions between age and HBeAg status, identifying differential predictors across demographic and virological strata. Kaplan–Meier survival curves illustrated hazard probabilities, further clarifying the timing and plateau effect of HBsAg clearance. By integrating multiple analytical strategies, the investigators avoided oversimplification and maintained biological fidelity.

The design reflects a careful balance between clinical reality and statistical sophistication. Although retrospective in nature, the study overcame common pitfalls by enforcing strict patient selection, leveraging long follow-up, and triangulating results across multiple regression models. This framework not only bolstered internal validity but also rendered the findings broadly interpretable within the wider field of HBV research. The methodological rigor supports confidence in the predictors identified and enables meaningful clinical translation.

Predictors of Functional Cure: Age, CD4 Counts, and HBeAg Positivity

The analysis revealed three baseline predictors that emerged consistently across logistic and Cox regression models: advanced age, elevated CD4 counts, and baseline HBeAg positivity. The association of advanced age with higher HBsAg clearance rates challenges intuitive expectations. While younger hosts generally possess more robust immune systems, older individuals in this cohort demonstrated a greater propensity for clearance. One explanation is cumulative immune adaptation, where chronic antigenic exposure over decades primes immune effector pathways to mount decisive control once ART stabilizes the viral environment. Another possibility is that age correlates with longer duration of viral equilibrium, allowing immune remodeling to favor clearance.

High CD4 counts at baseline were another critical determinant. CD4 T-cell recovery is central to effective immune reconstitution under ART, orchestrating both direct antiviral responses and coordination of cytotoxic CD8 and B-cell immunity. Patients who began therapy with relatively preserved CD4 reservoirs were better positioned to achieve functional cure, as their immune systems retained the capacity for adaptive recalibration. In contrast, those with profound depletion may have experienced irreversible immune exhaustion, limiting the capacity to clear HBsAg even under prolonged ART. This underscores the clinical imperative for earlier ART initiation in coinfected patients.

HBeAg positivity represented the third predictor, reflecting a distinct viral replicative state. HBeAg is associated with high HBV DNA replication and reduced chromosomal integration of viral DNA. Patients in this phase are immunologically more visible, providing targets for immune clearance once ART restores systemic function. Over time, mutations in the precore region eliminate HBeAg expression, producing a more insidious HBeAg-negative disease with fluctuating replication and higher integration events, rendering functional cure more elusive. Thus, baseline antigenic state determines the biological window of curability.

When combined into predictive models, these three factors produced strong discriminatory power, suggesting their integration into clinical algorithms could enhance patient stratification. Rather than relying solely on biochemical or virological readouts, physicians can contextualize treatment trajectories through the lens of age, immune status, and viral antigenicity. These predictors do not merely explain observed clearance events but provide a roadmap for guiding therapeutic expectations in future interventions.

Temporal Dynamics and the Plateau Effect in HBsAg Clearance

The temporal analysis revealed that HBsAg clearance rates surged during the early years of ART before stabilizing into a plateau around the eighth year of follow-up. This phenomenon reflects the initial potency of TDF-based regimens in reducing viral antigen loads, thereby unmasking HBV-infected hepatocytes to immune surveillance. The immune system, once recalibrated under ART, exerts maximal pressure within the first several years. Beyond this window, the rate of additional clearance diminishes, suggesting that residual HBsAg originates from stable chromosomally integrated HBV DNA resistant to immune or pharmacological eradication.

The plateau effect aligns with the concept of immune ceilings, where maximum clearance potential is achieved once ART restores equilibrium between viral replication and host immunity. In practical terms, this indicates that patients who do not achieve HBsAg loss within the first decade of treatment may have limited likelihood of subsequent clearance. Subgroup analyses demonstrated that the plateau was influenced by baseline factors, with older age and HBeAg positivity associated with earlier and higher clearance rates. These differences emphasize that temporal trajectories are not uniform but shaped by patient-specific biology.

Kaplan–Meier survival plots further illustrated that age ≥ 35 years and HBeAg-positive status at baseline yielded markedly higher cumulative hazard of clearance compared to younger and HBeAg-negative groups. This reinforced the notion that predictors interact with time, dictating not only the likelihood but also the timing of clearance events. The temporal stratification thus provides clinicians with dynamic markers for monitoring progress, enabling personalized treatment timelines rather than generalized prognostic statements.

The recognition of plateau dynamics also reframes the therapeutic horizon for functional cure. It implies that while ART is effective in creating conditions for clearance, pharmacological intervention alone may not suffice for all patients. Future curative strategies, including immune modulators or therapeutic vaccines, must target integrated HBV DNA or dormant reservoirs to push beyond the plateau. The Chinese cohort thus provides a biological benchmark for where ART efficacy peaks and where novel therapies must intervene.

Clinical Implications and Future Research Directions

The findings carry substantial implications for clinical practice and research. Identifying predictors of functional cure provides a practical framework for tailoring management in HIV/HBV coinfected patients. For clinicians, advanced age, preserved CD4 counts, and HBeAg positivity can guide both counseling and therapeutic prioritization. Patients meeting these profiles can be reassured about their higher likelihood of clearance, while those lacking predictors may be considered for experimental therapies or intensified monitoring. This stratification enhances resource allocation and aligns treatment goals with biological reality.

The plateau effect underscores the limitations of current therapeutic regimens and highlights the necessity for adjunctive interventions. Immune-based strategies, including checkpoint inhibitors, therapeutic vaccines, or adoptive T-cell therapies, may provide the additional impetus required to overcome persistent HBsAg. Similarly, curative drug design targeting covalently closed circular DNA (cccDNA) or chromosomally integrated sequences represents an urgent frontier. Integrating predictive biomarkers into trial design could optimize patient selection, accelerating the path toward scalable functional cure strategies.

For researchers, the study highlights the heterogeneity of clearance dynamics across ethnic and regional populations. Differences in HBV genotypes, host genetics, and treatment histories shape clearance outcomes, necessitating cross-cohort validation. The Chinese study complements findings from European, African, and Southeast Asian cohorts, collectively building a mosaic of predictive models. However, methodological uniformity across studies is essential to reconcile inconsistencies and produce universally applicable algorithms. Large-scale multinational collaborations will be critical for consolidating predictors into robust clinical tools.

Finally, the retrospective nature of the study underscores the importance of longitudinal prospective cohorts with complete virological and immunological data. Incorporating quantitative HBsAg measurements, HBV genotyping, and ART adherence monitoring will refine predictor accuracy. Functional cure remains an ambitious but attainable endpoint, requiring convergence of pharmacology, immunology, and virology. This study contributes a pivotal piece to the puzzle, guiding the next phase of curative research in HIV/HBV coinfection.

Study DOI: https://doi.org/10.3389/fcimb.2023.1130485

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES